Get the Daily Brief
Latest Biotech News
Multi‑cancer liquid biopsy research suggests earlier detection potential
New research reports that liquid biopsy technologies for multi‑cancer early detection (MCED) could enable screening across multiple cancer types outside current narrow protocols. Investigators...
Prenatal bifidobacterium supplementation alters preterm infant gut microbiome
Researchers reported that prenatal maternal supplementation with bifidobacterium produced measurable changes in the gut microbiome of preterm infants, particularly in pregnancies complicated by...
Recursion names new CEO as losses widen — cash runway extended
AI‑driven drug developer Recursion announced a leadership change, appointing Najat Khan, PhD as CEO while co‑founder Chris Gibson moves to chairman. The company reported mixed Q3 results: widening...
Merck’s oral PCSK9: up to 60% LDL drop in Phase 3
Merck reported Phase 3 data showing its oral PCSK9 inhibitor, enlicitide, reduced LDL cholesterol by up to 60% versus placebo. The trial enrolled about 2,900 patients at high cardiovascular risk...
Amgen’s Repatha: 25% fewer major CV events, 36% fewer first heart attacks
Amgen released VESALIUS‑CV results showing its PCSK9 antibody Repatha reduced major cardiovascular events by 25% in high‑risk patients and cut first heart attacks by 36%, data published in the New...
CRISPR in humans... LDL and triglycerides plunge in early trial
A first‑in‑human CRISPR gene‑editing therapy produced dramatic reductions in LDL cholesterol and triglycerides in an early study of 15 patients, according to STAT reporting from the AHA meeting...
Vir’s hepatitis D combo posts strong suppression; Phase 3 plans accelerate
Vir Biotechnology disclosed new data showing its combination regimen for chronic hepatitis D keeps viral levels low and supports an accelerated Phase 3 program, presented at AASLD. Company...
Pfizer tops Novo Nordisk with $10B Metsera bid – acquisition ends duel
Pfizer won a bidding war for obesity‑drug developer Metsera with an up‑to $10 billion proposal, offering $86.25 per share and edging out Novo Nordisk’s rival offer. The deal resolves an intense...
Recursion names Najat Khan CEO as cash runway extends into 2027
Recursion announced a leadership transition and mixed Q3 results: co‑founder Chris Gibson will become chairman while Najat Khan is set to take over as CEO. The company reported a larger net loss...
Amae Health raises $25M Series B to expand severe mental‑illness care
Behavioral‑health startup Amae Health closed a $25 million Series B led by Altos Ventures with participation from Quiet Capital, Bling Capital, Cedars‑Sinai Ventures, Healthier Capital and 8VC....
Patient advocates urge incentives for genetically targeted technologies (GTTs)
At BIO 2025’s PACE event, patient advocates and industry leaders pushed for policy incentives to protect development of genetically targeted technologies such as antisense oligonucleotides (ASOs)....
Sequential PD‑1 inhibitors improve outcomes after CD19 CAR‑T consolidation
A recent study led by Xue, Zhou and Chen found that using PD‑1 inhibitors as consolidative therapy after CD19 CAR‑T improved outcomes for patients with relapsed or refractory non‑Hodgkin lymphoma....
Toripalimab plus FLOT shows activity in peritoneal‑metastatic gastric cancer
A phase II trial reported that adding toripalimab, an anti‑PD‑1 antibody, to the FLOT chemotherapy backbone produced encouraging responses in gastric cancer patients with peritoneal metastasis....
Pfizer seals $10 billion takeover: Metsera deal ends bidding war
Pfizer agreed to buy obesity-drug developer Metsera for about $10 billion, topping a rival offer from Novo Nordisk and resolving a public bidding fight. The proposal offers up to $86.25 per share...
Merck’s oral PCSK9 pill slashes LDL up to 60%: Phase 3 data
Merck reported Phase 3 results showing its oral PCSK9 inhibitor reduced LDL cholesterol by as much as 60% in patients already on statins, meeting its long-sought goal of matching injectable...
Early CRISPR gene-editing lowers lipids in humans... but safety questions remain
An early-stage CRISPR-based therapy dramatically reduced LDL cholesterol and triglycerides in a small cohort of patients with heart disease, investigators reported at the American Heart...
Amgen’s Repatha prevents first heart attacks: detailed VESALIUS-CV results
Amgen disclosed detailed VESALIUS-CV trial data showing its PCSK9 monoclonal antibody Repatha reduced major cardiovascular events by 25% and prevented first heart attacks by 36% in high-risk...
Vir presents hepatitis D combo data: Phase 3 program accelerated
Vir Biotechnology reported new data showing its combination regimen for chronic hepatitis D maintains low viral levels, reinforcing the therapy’s potential as clinical studies advance. The company...
Recursion names new CEO as losses widen — cash runway extended to 2027
AI-driven drug developer Recursion announced a leadership transition and an improved cash position that extends runway into 2027. Co-founder Chris Gibson will step down as CEO to become board...
Amae Health raises $25M to scale care for severe mental illness
Amae Health closed a $25 million Series B led by Altos Ventures with participation from Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital and 8VC to expand its care model for...